Elucidating the mechanism of action of pregabalin: α 2δ as a therapeutic target in Anxiety

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 637-648

  Micó, Juan Antonio ^a   Prieto, Rita ^a,b  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b PFIZER INC   (United States)

Author keywords

Anxiety; Generalized anxiety disorder; Pregabalin.

Indexed keywords

ALPHA2DELTA TYPE 1 PROTEIN; CALCIUM ION; GLUTAMIC ACID; NEUROTRANSMITTER; PREGABALIN; PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AMYGDALOID NUCLEUS; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN REGION; CALCIUM CURRENT; CEREBELLUM; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EPILEPSY; EXOCYTOSIS; GENERALIZED ANXIETY DISORDER; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IN VIVO STUDY; MEMBRANE FUSION; NAUSEA; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OLFACTORY BULB; PAIN; POINT MUTATION; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SPINAL CORD DORSAL HORN; STRUCTURE ACTIVITY RELATION; SYNAPSE VESICLE; SYNAPTOGENESIS; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BRAIN; CALCIUM CHANNELS; GAMMA-AMINOBUTYRIC ACID; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863697256     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634510-000000000-00000     Document Type: Article

References (101)

1. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005 Aug; 15 (4): 357-76
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 617-27
3. Ansseau M, Fischler B, Dierick M, et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 2005 May; 20 (3): 229-35
4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 593-602
5. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl. 8: 24-34
6. Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004; 65 Suppl. 13: 20-6
7. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007 Mar; 146 (5): 317-25
8. Ansseau M, Fischler B, Dierick M, et al. Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II). Depress Anxiety 2008; 25 (6): 506-13
9. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005 Jun; 162 (6): 1179-87
10. Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999 Dec; 156 (12): 1915-23
11. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25 (1): 72-90
12. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007 Nov; 21 (8): 864-72
13. Martin EI, Ressler KJ, Binder E, et al. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Clin Lab Med 2010 Dec; 30 (4): 865-91
14. Andrade R. Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology 2011 Sep; 61 (3): 382-6
15. Haefely W. Benzodiazepine interactions with GABA receptors. Neurosci Lett 1984 Jun; 47 (3): 201-6
16. Stéru L, Chermat R, Millet B, et al. Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects. Epilepsia 1986; 27 Suppl. 1: S14-7
17. Reiner PB, Kamondi A. Mechanisms of antihistamineinduced sedation in the human brain: H1 receptor acti-vation reduces a background leakage potassium current. Neuroscience 1994 Apr; 59 (3): 579-88
18. Kubo N, Shirakawa O, Kuno T, et al. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol 1987 Mar; 43 (3): 277-82
19. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010 May; 25 (3): 117-31
20. Yuen PW. Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant. Bioorg Med Chem Lett 1994; 4: 823-6
21. Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for a2d-1 and a2d-2 calcium channel subunits. Eur J Pharmacol 2011 Sep; 667 (1-3): 80-90
22. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010 Aug; 50 (8): 941-50
23. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2-d (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007 Feb; 73 (2): 137-50
24. Piyapolrungroj N, Li C, Bockbrader H, et al. Mucosal uptake of gabapentin (Neurontin) vs pregabalin in the small intestine. Pharm Res 2001 Aug; 18 (8): 1126-30
25. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol 2007 Oct; 20 (5): 456-72
26. Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008 Jul; 8 (7): 1013-24
27. Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (a2-d) ligand for the management of fibromyalgia. Am J Manag Care 2010 May; 16 (5 Suppl.): S138-43
28. Montgomery SA, Kasper S. Pharmacotherapy update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Ther 2010; 2: 189-202
29. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003 Mar; 160 (3): 533-40
30. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003 Jun; 23 (3): 240-9
31. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005 Apr; 25 (2): 151-8
32. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005 Sep; 62 (9): 1022-30
33. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006 May; 67 (5): 771-82
34. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009 Mar; 24 (2): 87-96
35. Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008 Nov; 193 (5): 389-94
36. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008 Jan; 23 (1): 18-28
37. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo-and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol 2009 Nov; 23 (8): 867-73
38. Stein DJ, Lydiard RB, Herman BK, et al. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009 May; 24 (3): 126-32
39. Lydiard RB, Rickels K, Herman B, et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010 Mar; 13 (2): 229-41
40. Montgomery SA, Herman BK, Schweizer E, et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009 Jul; 24 (4): 214-22
41. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005 Feb; 28 (2): 187-93
42. Hadley SJ, Mandel FS, Schweizer E. Switching from longterm benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2012 Apr; 26 (4): 461-70
43. Davies A, Kadurin I, Alvarez-Laviada A, et al. The a2d subunits of voltage-gated calcium channels form GPIanchored proteins, a posttranslational modification essential for function. Proc Natl Acad Sci USA 2010 Jan; 107 (4): 1654-9
44. Davies A, Hendrich J, Van Minh AT, et al. Functional biology of the a2d subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007 May; 28 (5): 220-8
45. Bauer CS, Tran-Van-Minh A, Kadurin I, et al. A new look at calcium channel a2d subunits. Curr Opin Neurobiol 2010 Oct; 20 (5): 563-71
46. Gong HC, Hang J, Kohler W, et al. Tissue-specific expression and gabapentin-binding properties of calcium channel a2d subunit subtypes. J Membr Biol 2001 Nov; 184 (1): 35-43
47. Marais E, Klugbauer N, Hofmann F. Calcium channel a2d subunits: structure and gabapentin binding. Mol Pharmacol 2001 May; 59 (5): 1243-8
48. Qin N, Yagel S, Momplaisir ML, et al. Molecular cloning and characterization of the human voltage-gated calcium channel a2d-4 subunit. Mol Pharmacol 2002 Sep; 62 (3): 485-96
49. Li Z, Taylor CP, Weber M, et al. Pregabalin, a novel anticonvulsant, analgesic, and anxiolytic drug, exhibits class-specific alpha2-delta-1 and alpha2-delta-2 calcium channel subunit binding [abstract]. Soc Neurosci Abstr Program 2004; 115.11
50. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003; 64 Suppl. 13: 5-12
51. Bian F, Li Z, Offord J, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 2006 Feb; 1075 (1): 68-80
52. Li Z, Donevan S, Taylor CP, et al. High-affinity binding of pregabalin at alpha-2-delta subunits of voltage-gated calcium channel: contribution to anticonvulsant action [abstract]. Epilepsia 2005; 46: 280
53. Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (a2-d) type 1 protein. Neuroscience 2008 Aug; 155 (2): 510-21
54. Wise RG, Lujan BJ, Schweinhardt P, et al. The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI. Magn Reson Imaging 2007 Jul; 25 (6): 801-10
55. Paulus MP, Feinstein JS, Castillo G, et al. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 2005 Mar; 62 (3): 282-8
56. Arce E, Simmons AN, Lovero KL, et al. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 2008 Mar; 196 (4): 661-72
57. Simmons AN, Arce E, Lovero KL, et al. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol 2009 Sep; 12 (8): 1009-20
58. Windischberger C, Lanzenberger R, Holik A, et al. Areaspecific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 2010 Jan; 49 (2): 1161-70
59. Aupperle RL, Ravindran L, Tankersley D, et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology 2011 Jun; 36 (7): 1466-77
60. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010 Jan; 35 (1): 169-91
61. Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogs that target the a2-d protein. J Med Chem 2005 Apr; 48 (7): 2294-307
62. Lotarski SM,Donevan S, El-Kattan A, et al. Anxiolytic-like activity of pregabalin in the Vogel conflict test in a2d-1 (R217A) and a2d-2 (R279A) mouse mutants. J Pharmacol Exp Ther 2011 Aug; 338 (2): 615-21
63. Data on file, Pfizer Inc., 2008
64. Boroujerdi A, Kim HK, Lyu YS, et al. Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain 2008 Oct; 139 (2): 358-66
65. Boroujerdi A, Zeng J, Sharp K, et al. Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain 2011 Mar; 152 (3): 649-55
66. Li CY, Song YH, Higuera ES, et al. Spinal dorsal horn calcium channel a2d-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004 Sep; 24 (39): 8494-9
67. N'Gouemo P, Yasuda R, Faingold CL. Seizure susceptibility is associated with altered protein expression of voltage-gated calcium channel subunits in inferior colliculus neurons of the genetically epilepsy-prone rat. Brain Res 2010 Jan; 1308: 153-7
68. Fink K, Meder W, Dooley DJ, et al. Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000 Jun; 130 (4): 900-6
69. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002 Feb; 42 (2): 229-36
70. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000 Feb; 280 (2): 107-10
71. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001 Aug; 93 (2): 191-6
72. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001 Sep; 134 (2): 237-40
73. Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004 Sep; 20 (6): 1566-76
74. Coderre TJ, Kumar N, Lefebvre CD, et al. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005 Aug; 94 (4): 1131-9
75. Dooley DJ, Donovan CM, Pugsley TA. Stimulusdependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000 Dec; 296 (3): 1086-93
76. Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltagesensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002 Sep; 45 (3): 171-90
77. Kłodziń ska A, Tatarczyń ska E, Stachowicz K, et al. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu1 receptor antagonist. J Physiol Pharmacol 2004 Mar; 55 (1 Pt 1): 113-26
78. Steckler T, Lavreysen H, Oliveira AM, et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005 Apr; 179 (1): 198-206
79. Rorick-Kehn LM, Hart JC, McKinzie DL. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl) 2005 Dec; 183 (2): 226-40
80. Varty GB, Grilli M, Forlani A, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005 Apr; 179 (1): 207-17
81. Lima VC, Molchanov ML, Aguiar DC, et al. Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jan; 32 (1): 178-85
82. Satow A, Maehara S, Ise S, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-luoropyridine-3-yl) -5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H) -carboxamide]. J Pharmacol Exp Ther 2008 Aug; 326 (2): 577-86
83. Kotlinska J, Bochenski M. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 2008 Nov; 598 (1-3): 57-63
84. Navarro JF, De Castro V, Mart́n-Ló pez M. JNJ16259685, a selective mGlu1 antagonist, suppresses isolationinduced aggression in male mice. Eur J Pharmacol 2008 May; 586 (1-3): 217-20
85. Eroglu C, Allen NJ, Susman MW, et al. Gabapentin receptor a2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009 Oct; 139 (2): 380-92
86. Christopherson KS, Ullian EM, Stokes CC, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 2005 Feb; 120 (3): 421-33
87. Li CY, Zhang XL, Matthews EA, et al. Calcium channel a2d1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006 Nov; 125 (1-2): 20-34
88. Prince DA. Epileptogenic neurons and circuits. Adv Neurol 1999; 79: 665-84
89. Field MJ, Cox PJ, Stott E, et al. Identification of the a2-d-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006 Nov; 103 (46): 17537-42
90. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the a2d ligand gabapentin. Proc Natl Acad Sci USA 2008 Mar; 105 (9): 3628-33
91. Tran-Van-Minh A, Dolphin AC. The a2d ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit a2d-2. J Neurosci 2010 Sep; 30 (38): 12856-67
92. Martin DJ, McClelland D, Herd MB, et al. Gabapentinmediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropharmacology 2002 Mar; 42 (3): 353-66
93. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003 Sep; 105 (1-2): 133-41
94. Brown JT, Randall A. Gabapentin fails to alter P/Q-type Ca2+ channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 2005 Mar; 55 (4): 262-9
95. Gauchan P, Andoh T, Ikeda K, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel a2d-1 subunit. Biol Pharm Bull 2009 Apr; 32 (4): 732-4
96. Abe M, Kurihara T, Han W, et al. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine 2002 Jul; 27 (14): 1517-24
97. Eutamene H, Coelho AM, Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000 Oct; 295 (1): 162-7
98. Stanfa LC, Singh L, Williams RG, et al. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 1997 Feb; 8 (3): 587-90
99. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel a2d ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007 Feb; 28 (2): 75-82
100. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001 Aug; 93 (2): 191-6
101. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 2004 Apr; 46 (5): 743-9